Print  |  Close

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications


Active: Yes
Cancer Type: Breast Cancer NCT ID: NCT01772004
Trial Phases: Phase I Protocol IDs: EMR 100070-001 (primary)
2013-002834-19
Eligibility: 18 and older, Male and Female Study Type: Treatment
Study Sponsor: EMD Serono
NCI Full Details:

Summary

This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.